Covid 19 Research using Clinical Trials (Home Page)
Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)Wiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (0)
|
Name (Synonyms) |
Correlation |
Correlated MeSH Terms (0)
|
Name (Synonyms) |
Correlation |
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There is one clinical trial.
Clinical Trials
To characterize the ability of the D2000 Cartridge in combination with the Optia SPD Protocol
to reduce the morbidity and mortality associated with SARS-CoV-2 infection in patients
admitted to the ICU.
NCT04358003 Respiratory Failure ARDS Device: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)
Primary Outcomes
Measure: All-cause mortality Time: Day 28
Secondary Outcomes
Description: Scale of 0-24 with a higher number indicating a worse outcome
Measure: Change in Sequential Organ Failure Assessment [SOFA] scores
Time: Day 28
No related HPO nodes (Using clinical trials)